Idorsia Pharmaceuticals Ltd.

Migration, Crosslink

📖

Idorsia Pharmaceuticals Ltd.

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-idorsia-pharmaceuticals

📖 Wiki Page

company3906 wordssynced 2026-04-02

Overview

flowchart TD companies_idorsia_pharmaceutic["Idorsia Pharmaceuticals Ltd."] style companies_idorsia_pharmaceutic fill:#4fc3f7,stroke:#333,color:#000 companies_idorsia_ph_0["Company Overview"] companies_idorsia_pharmaceutic -->|"includes"| companies_idorsia_ph_0 style companies_idorsia_ph_0 fill:#81c784,stroke:#333,color:#000 companies_idorsia_ph_1["Corporate History"] companies_idorsia_pharmaceutic -->|"includes"| companies_idorsia_ph_1 style companies_idorsia_ph_1 fill:#ef5350,stroke:#333,color:#000 companies_idorsia_ph_2["Spin-off from Actelion"] companies_idorsia_pharmaceutic -->|"includes"| companies_idorsia_ph_2 style companies_idorsia_ph_2 fill:#ffd54f,stroke:#333,color:#000 companies_idorsia_ph_3["Company Background"] companies_idorsia_pharmaceutic -->|"includes"| companies_idorsia_ph_3 style companies_idorsia_ph_3 fill:#ce93d8,stroke:#333,color:#000 companies_idorsia_ph_4["Founding and Leadership"] companies_idorsia_pharmaceutic -->|"includes"| companies_idorsia_ph_4 style companies_idorsia_ph_4 fill:#4fc3f7,stroke:#333,color:#000 companies_idorsia_ph_5["Neuroscience"] companies_idorsia_pharmaceutic -->|"includes"| companies_idorsia_ph_5 style companies_idorsia_ph_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Idorsia Pharmaceuticals Ltd. is a Swiss biotechnology company headquartered in Allschwil, near Basel, Switzerland["@idorsia2026"]. Founded in 2017 as a spin-off from Actelion Pharmaceuticals following Johnson & Johnson's acquisition of Actelion, Idorsia has established itself as a leading innovator in the development of novel therapeutics for diseases with significant unmet medical needs["@actelion_spin"]. The company leverages a disciplined drug discovery approach combining advanced small molecule chemistry, target validation using human genetics, and global clinical development capabilities to bring breakthrough treatments to patients worldwide["@idorsia2026a"]. Idorsia Pharmaceuticals Ltd. is a Swiss biotech company headquartered in Allschwil, near Basel, Switzerland["@idorsia2026"]. The company was founded in 2017 as a spin-off from Actelion following Johnson & Johnson's acquisition of Actelion, and has developed into a leading biopharmaceutical company focused on innovative therapies for diseases with high unmet medical needs["@idorsia2026a"].

With a diversified pipeline spanning neuroscience, immunology, and oncology, Idorsia has established itself as one of Europe's most promising biotech companies. The company's lead product, daridorexant (brand name Quviviq), represents a novel approach to insomnia treatment and has received regulatory approval in multiple jurisdictions including the United States, Europe, and Japan.

Company Overview

| Attribute | Details |
|-----------|---------|
| Headquarters | Allschwil, Switzerland |
| Founded | 2017 |
| Stock Symbol | SIX: IDIA |
| Employees | ~800 |
| CEO | Jean-Paul Clozel |
| Market Cap | ~CHF 1-2 billion |

Corporate History

Spin-off from Actelion

Idorsia's origins trace to Actelion, a Swiss pharmaceutical company founded in 1997 by Jean-Paul Clozel and his wife Martine Clozel. Actelion built a successful portfolio of specialty medicines, particularly in pulmonary hypertension and rare diseases, ultimately growing into one of Europe's largest biotech companies.

In 2017, Johnson & Johnson announced its intention to acquire Actelion for approximately $30 billion. As part of the transaction, the Clozels and several key scientific leaders negotiated to spin out certain early-stage research programs into a new company, which became Idorsia.

Idorsia's research portfolio spans multiple therapeutic domains, including central nervous system (CNS) disorders, cardiovascular diseases, immunological conditions, and rare diseases. Within neuroscience, the company has gained particular recognition for its development of daridorexant (marketed as Quviviq), a dual orexin receptor antagonist that represents a novel approach to treating insomnia by targeting the orexinergic system rather than the GABAergic pathways used by traditional sedative-hypnotics[@quviviq_fda].

Company Background

Founding and Leadership

Idorsia maintains a diversified pipeline focusing on:

Neuroscience

The neuroscience division represents Idorsia's most advanced and strategically important portfolio:

Sleep disorders: Daridorexant for insomnia, a novel dual orexin receptor antagonist
Alzheimer's disease: Exploring orexin modulation for disease modification
Parkinson's disease: Sleep-focused interventions for neurodegenerative symptoms

Immunology

Idorsia's immunology pipeline targets inflammatory and autoimmune diseases.

Oncology

The oncology portfolio focuses on novel therapeutic approaches.

Neurodegeneration Strategy

Sleep and Neurodegeneration Link

The connection between sleep disorders and neurodegenerative diseases represents one of the most important frontiers in neuroscience research. Idorsia's therapeutic approach leverages this connection through orexin receptor modulation.

Key scientific findings supporting this approach:

Glymphatic clearance: Sleep, particularly slow-wave sleep, activates the glymphatic system—the brain's waste clearance mechanism—enabling removal of neurotoxic proteins including amyloid-beta and alpha-synuclein[@xie2013][@nedergaard2022]

Amyloid dynamics: Studies using PET imaging have demonstrated that one night of sleep deprivation increases amyloid plaque burden in human hippocampus[@lucidi2023]

Tau propagation: Sleep disruption accelerates tau pathology spread

Neuroinflammation: Chronic sleep deprivation promotes neuroinflammation, creating an environment favorable to neurodegenerative processes[@irwin2020]

Orexin system role: The orexin neuropeptide system, which regulates wakefulness, also influences amyloid and tau metabolism[@gupta2023]

Daridorexant Mechanism

Daridorexant is a dual orexin receptor antagonist (DORA) that competitively blocks both orexin receptors, reducing wakefulness drive and promoting sleep onset and maintenance[@jaehne2022][@sherman2022].

Pharmacological properties:

Dual receptor targeting: Blocks both OX1R and OX2R for comprehensive sleep promotion
Rapid absorption: Tmax of approximately 1-2 hours
Optimized half-life: Approximately 8-10 hours enabling sustained sleep through the night
No next-day residual: Designed to minimize morning sedation

The approval of daridorexant (Quviviq) in 2022 represented the culmination of over a decade of development and positioned Idorsia as a leader in sleep medicine.

Pipeline Overview

Idorsia was established in 2017 when Actelion's parent company Johnson & Johnson acquired Actelion for approximately $30 billion and subsequently spun out Idorsia as an independent entity. This spin-off ensured continuity of Actelion's research pipeline and retained the scientific expertise developed over decades of drug discovery[@clozel2017]. The company's leadership includes several former Actelion executives, most notably CEO Jean-Paul Clozel, who previously led Actelion from its founding through its growth into a major pharmaceutical company[@idorsia2026c].

The transition from Actelion to Idorsia preserved access to extensive compound libraries, proprietary screening platforms, and established clinical development infrastructure, enabling Idorsia to launch with a diversified pipeline of drug candidates across multiple therapeutic areas[@idorsia2026a].

Corporate Structure and Operations

| Attribute | Details |
|-----------|---------|
| Headquarters | Allschwil, Basel-Landschaft, Switzerland |
| Founded | 2017 |
| Stock Exchange | SIX Swiss Exchange (IDIA) |
| Employees | Approximately 500+ |
| Focus Areas | CNS, Cardiovascular, Immunology, Rare Diseases | Indication: Insomnia Disorder

Status: Approved (US, EU, Japan)

Mechanism: Dual orexin receptor antagonist

Daridorexant represents Idorsia's first approved therapeutic. The drug has demonstrated clinically meaningful improvement in sleep onset and maintenance, favorable safety profile without next-day impairment, no evidence of dependence or withdrawal symptoms, and efficacy maintained in long-term extension studies.

ACT-462206

Indication: Sleep disorder in neurodegenerative disease

Status: Phase 2 planning

This program explores the use of orexin modulation in patients with neurodegenerative disease, particularly Alzheimer's and Parkinson's disease.

Clinical Development in Neurodegeneration

Rationale for Neurodegeneration Applications

The exploration of orexin modulation in Alzheimer's and Parkinson's disease builds on robust scientific rationale:

Alzheimer's Disease:

Amyloid clearance: Enhanced sleep, particularly deep slow-wave sleep, increases glymphatic clearance of amyloid-beta from the brain[@xie2013]

Tau dynamics: Sleep deprivation accelerates tau pathology propagation

Neuroinflammation: Sleep disruption promotes neuroinflammatory processes through microglial activation

Cognitive function: Sleep quality directly correlates with cognitive performance in AD patients

Parkinson's Disease:

Alpha-synuclein clearance: Similar glymphatic mechanisms may facilitate clearance of alpha-synuclein aggregates

REM behavior disorder: RBD often precedes motor symptoms by years; treating sleep disorders may delay progression

Non-motor symptoms: Sleep disorders are among the most disabling non-motor symptoms in PD

Neuroprotection: Orexin modulation may offer direct neuroprotective effects beyond sleep improvement

The company operates from its state-of-the-art research facility in Allschwil, which houses discovery biology, medicinal chemistry, and early development capabilities. Idorsia maintains clinical development operations across North America, Europe, and Asia-Pacific regions[@idorsia2026a].

Therapeutic Areas and Pipeline

Central Nervous System

Idorsia's CNS portfolio represents a significant portion of its clinical pipeline, with particular emphasis on sleep disorders and exploring the intersection of sleep biology with neurodegenerative disease mechanisms[@idorsia_pipeline].

Daridorexant (ACT-541468 / Quviviq)

Daridorexant is Idorsia's most advanced CNS candidate and represents a first-in-class therapeutic for insomnia disorder. Approved by the US Food and Drug Administration in January 2022, daridorexant is a dual orexin receptor antagonist (DORA) that works by blocking the orexin neuropeptides Orexin-A and Orexin-B from binding to their receptors (OX1R and OX2R)[@quviviq_fda][@idorsia2026b].

The orexinergic system plays a critical role in regulating wakefulness. Orexin-producing neurons in the lateral hypothalamus project throughout the brain and spinal cord, releasing neuropeptides that promote arousal and maintain wakefulness. In insomnia, this system is hyperactive, resulting in difficulty initiating or maintaining sleep. By antagonizing orexin receptors, daridorexant reduces this wake-promoting signaling, facilitating sleep onset and maintenance without the dependence and next-day sedation associated with traditional sedative medications[@bove2015].

Clinical Development Program:

Phase 1: Single and multiple ascending dose studies establishing safety and pharmacokinetics
Phase 2: Dose-ranging studies demonstrating efficacy in insomnia patients
Phase 3: Two pivotal trials (SUNRISE 1 and SUNRISE 2) demonstrating efficacy and safety
FDA Approval: January 2022
EMA Approval: 2022

Sleep and Neurodegeneration: Emerging Research Connection

While daridorexant is indicated for insomnia, growing evidence suggests that the drug class may have implications for neurodegenerative disease progression through multiple mechanisms[@he2022]. Idorsia's research program has explored these connections, contributing to understanding the bidirectional relationship between sleep and neurodegeneration[@eckert2019].

Mechanism 1: Glymphatic Clearance Enhancement

The glymphatic system, first characterized by Maiken Nedergaard and colleagues, is a macroscopic waste clearance system in the brain that operates primarily during sleep[@nedergaard2013]. This system utilizes perivascular channels formed by astroglial endfeet to facilitate the bulk flow of cerebrospinal fluid through brain parenchyma, enabling clearance of metabolic waste products including amyloid-beta (Aβ) and tau proteins[@iliff2013].

Xie et al. demonstrated that the glymphatic system functions predominantly during slow-wave sleep, with glymphatic flow increasing by more than 60% during this sleep stage compared to wakefulness[@xie2013]. This finding has profound implications for understanding the relationship between sleep disturbances and neurodegenerative diseases, as chronic sleep disruption could impair clearance of neurotoxic proteins implicated in Alzheimer's disease (AD) and Parkinson's disease (PD)[@fultz2019].

Mechanism 2: Amyloid-Beta Dynamics

Kang et al. demonstrated that orexinergic signaling directly influences amyloid-beta production and clearance dynamics[@kang2009]. Their research showed that:

Orexin administration increases Aβ levels in brain interstitial fluid
Sleep deprivation enhances amyloid plaque formation in APP/PS1 transgenic mice
Genetic orexin deficiency reduces amyloid deposition
Orexin receptor antagonism may reduce Aβ production

This research suggests that orexin antagonists like daridorexant could potentially influence AD pathology through modulation of the orexin system, although this remains an area of active investigation and not a clinically established indication[@tracey2017].

Mechanism 3: Tau Propagation

Recent research has revealed that tau protein pathology spreads along neural circuits in a prion-like manner, with neuronal activity influencing tau transmission and accumulation[@holth2019]. Sleep deprivation has been shown to:

Increase neuronal excitability
Enhance tau propagation between neurons
Accelerate tau pathology in animal models

These findings suggest that improving sleep quality through orexin antagonism might indirectly influence tau pathology progression, though clinical evidence remains preliminary[@ju2016].

Other CNS Programs

Idorsia's pipeline includes additional neuroscience candidates at various stages of development[@idorsia_pipeline]:

ACT-xxx: Preclinical program targeting cognitive disorders associated with neurodegenerative diseases
ACT-xxx: Research program investigating sleep-wake cycle regulation in neurological conditions
Partnership programs: Collaborative development with academic and pharmaceutical partners

Cardiovascular Diseases

Aprocitentan (ACT-541468)

Aprocitentan is a dual endothelin receptor antagonist being developed for the treatment of resistant hypertension. This compound represents a novel mechanism for blood pressure control, targeting the endothelin pathway that plays a key role in vascular tone and blood pressure regulation[@idorsia_pipeline].

Endothelin-1 (ET-1) is one of the most potent vasoconstrictive peptides identified and is implicated in the pathophysiology of hypertension, pulmonary arterial hypertension, and cardiovascular remodeling. By blocking both ETA and ETB receptors, aprocitentan provides comprehensive inhibition of endothelin-mediated vasoconstriction[@idorsia2026a].

Clinical Development:

Phase 2: Dose-ranging studies in resistant hypertension
Phase 3: pivotal trials demonstrating blood pressure reduction
FDA Review: Ongoing

Rare Diseases

Lucerastat (ACT-541468)

Lucerastat is an oral small molecule inhibitor of glucosylceramide synthase being developed for the treatment of Fabry disease, a rare lysosomal storage disorder caused by deficiency of the enzyme alpha-galactosidase A (α-Gal A). This deficiency leads to accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids in various tissues, causing progressive organ damage[@idorsia_pipeline].

By inhibiting glucosylceramide synthase, the rate-limiting enzyme in glycosphingolipid biosynthesis, lucerastat reduces substrate accumulation even in patients with residual enzyme activity. This substrate reduction approach offers potential benefits for patients with missense mutations that result in some residual enzyme function[@idorsia2026a].

Clinical Development:

Phase 1/2: Open-label studies in Fabry disease patients
Phase 3: Ongoing clinical trials
Orphan Drug Designation: FDA and EMA

Immunology

Idorsia maintains active immunology programs targeting inflammatory and autoimmune conditions. These programs leverage the company's expertise in small molecule drug discovery and GPCR biology to develop novel anti-inflammatory agents[@idorsia_pipeline].

Research Platform and Capabilities

Drug Discovery Approach

Idorsia employs an integrated drug discovery platform combining multiple approaches[@idorsia2026a]:

| Capability | Description |
|------------|-------------|
| Target Identification | Human genetics validation, pathway analysis |
| High-Throughput Screening | Large compound library for novel hit identification |
| Medicinal Chemistry | Structure-activity relationship optimization |
| In vivo Pharmacology | Translational models including genetically engineered mice |
| Clinical Development | Global Phase 1-3 trial capabilities |

Key Scientific Expertise

The company's research capabilities span several core areas:

GPCR Biology: Idorsia's heritage from Actelion includes extensive expertise in G protein-coupled receptor (GPCR) drug discovery. Many successful drugs target GPCRs, and Idorsia continues to leverage this expertise to develop novel modulators of GPCR signaling for unmet medical needs.

Ion Channel Modulation: The company maintains capabilities in developing small molecules that modulate ion channel activity, important for neurological and cardiovascular applications.

Kinase Inhibition: While primarily focused on GPCRs, Idorsia has explored kinase targets relevant to inflammatory and oncological conditions.

Partnerships and Collaborations

Janssen Biotech (Johnson & Johnson)

Idorsia has established a strategic partnership with Janssen Biotech for the development and commercialization of certain neuroscience programs. This relationship derives from the original Actelion transaction and provides Idorsia with access to Janssen's global development and commercialization infrastructure[@idorsia2026a].

Academic Collaborations

The company maintains active collaborations with leading academic institutions for:

Target discovery and validation
Translational biomarker development
Clinical proof-of-concept studies
Basic neuroscience research

Pharmaceutical Partnerships

Idorsia has established licensing and collaboration agreements with major pharmaceutical companies for specific programs, providing both funding support and strategic access to global markets.

Financial Overview

Idorsia is publicly traded on the SIX Swiss Exchange under the ticker symbol IDIA. The company's financial position reflects its focus on clinical development while maintaining disciplined capital allocation[@idorsia2026a].

| Metric | Status |
|--------|--------|
| Market Cap | ~CHF 1-2 billion (varies with market conditions) |
| Cash Position | Sufficient for ongoing clinical development |
| Revenue | Product sales (Quviviq) and potential milestones |
| R&D Investment | Significant ongoing investment in clinical trials |

Sleep, Neurodegeneration, and Future Directions

Bidirectional Relationship Between Sleep and Neurodegeneration

The relationship between sleep and neurodegenerative diseases represents one of the most active areas of neuroscience research[@eckert2019]. Epidemiological studies have consistently demonstrated that:

Sleep disturbances precede cognitive decline in AD
Chronic insomnia increases dementia risk
Sleep quality deteriorates years before clinical diagnosis

This bidirectional relationship involves multiple mechanisms:

Sleep-Dependent Clearance: The glymphatic system operates primarily during sleep, particularly during slow-wave sleep[@xie2013]. Impaired sleep therefore reduces clearance of neurotoxic proteins including amyloid-beta and tau. Research by Iliff et al. demonstrated that astroglial AQP4 water channels facilitate this perivascular flow, and disruption of this pathway impairs clearance[@iliff2013].

Neuronal Activity and Pathology: Sleep deprivation increases neuronal activity, which has been shown to accelerate tau pathology propagation[@holth2019]. Studies in animal models demonstrate that sleep loss enhances excitotoxicity and accelerates neurodegenerative processes.

Circadian Regulation: The suprachiasmatic nucleus regulates circadian rhythms, and disruption of circadian function has been linked to neurodegeneration. Orexinergic signaling provides one mechanistic link between circadian regulation and sleep-wake cycles.

Clinical Implications

While the relationship between orexin antagonism and neurodegeneration remains under investigation, several clinical observations are relevant:

Alzheimer's Disease: Patients with AD frequently exhibit sleep disturbances, including insomnia, sleep fragmentation, and circadian rhythm disruptions. These disturbances may contribute to disease progression through impaired glymphatic clearance[@ju2016].

Parkinson's Disease: Sleep disorders are among the earliest prodromal symptoms of PD, with rapid eye movement (REM) sleep behavior disorder (RBD) considered a significant risk factor. The orexinergic system may play roles in PD pathophysiology[@he2022].

Clinical Trial Considerations: Current trials of orexin antagonists in insomnia populations provide opportunities to longitudinally monitor cognitive outcomes, though such analyses require extended follow-up periods.

Future Research Directions

Idorsia's research program continues to explore the connections between sleep biology and neurodegenerative diseases, with several potential directions:

Biomarker studies: Characterizing sleep-dependent changes in cerebrospinal fluid biomarkers
Long-term outcome studies: Monitoring cognitive trajectories in insomnia patients treated with orexin antagonists
Combination approaches: Exploring whether orexin antagonism could complement disease-modifying therapies for AD and PD

Competitive Landscape

Orexin Antagonist Market

Idorsia's daridorexant competes with other orexin receptor antagonists in the insomnia market:

| Drug | Company | Approval Year | Status |
|------|---------|---------------|--------|
| Suvorexant | Merck (Belsomra) | 2014 | Marketed |
| Lemborexant | Eisai (Dayvigo) | 2019 | Marketed |
| Daridorexant | Idorsia (Quviviq) | 2022 | Marketed |

Each orexin antagonist has distinct pharmacokinetic properties and receptor binding profiles. Daridorexant's long half-life provides sustained efficacy throughout the night, addressing both sleep onset and sleep maintenance[@idorsia2026b].

Differentiating Factors

Idorsia's competitive position in the sleep disorder market relies on several factors:

Novel Mechanism: Dual orexin receptor antagonism represents a first-in-class approach for insomnia with a distinct pharmacological profile

Clinical Efficacy: Pivotal trials demonstrated significant improvements in sleep onset and maintenance endpoints

Safety Profile: Lack of next-day sedation distinguishes orexin antagonists from traditional GABAergic hypnotics

Intellectual Property: Composition of matter patents provide market protection through the 2030s

Neurodegeneration Research Competition

In the broader neurodegeneration space, Idorsia's research connects to a competitive landscape including:

Sleep-Enhancing Technologies: Devices, behavioral interventions, and other pharmacological approaches targeting sleep quality
Glymphatic Enhancement: Research programs exploring pharmacological and device-based approaches to enhance glymphatic clearance
Orexin Modulation: Academic and industry programs investigating orexin pathways in neurodegeneration

Clinical Development Programs

Daridorexant Clinical Trial Program

The daridorexant development program included extensive clinical trials establishing efficacy and safety:

Phase 1 Studies:

Single ascending dose (SAD) in healthy volunteers
Multiple ascending dose (MAD) in healthy volunteers
Food effect study
Drug interaction studies

Phase 2 Studies:

Dose-ranging study in insomnia patients
Proof-of-concept for sleep maintenance

Phase 3 Studies (SUNRISE Program):

SUNRISE 1: 8-week randomized controlled trial in insomnia disorder
SUNRISE 2: 12-month open-label extension safety study
Both trials met primary and key secondary endpoints

Ongoing Post-Marketing Studies:

Real-world effectiveness studies
Long-term safety monitoring
Cognitive outcome substudies

Aprocitentan Clinical Trial Program

The aprocitentan development program for resistant hypertension included:

Phase 2 Studies:

Dose-ranging studies establishing optimal dosing
Combination therapy studies with standard antihypertensives

Phase 3 Program (PRECISION):

Pivotal trial in resistant hypertension
Cardiovascular outcome substudies

Lucerastat Clinical Trial Program

The lucerastat program for Fabry disease included:

Phase 1/2 Studies:

Safety and pharmacokinetics in healthy volunteers and Fabry patients
Biomarker studies demonstrating substrate reduction

Phase 3 Studies (MODIFY):

Pivotal trials in patients with confirmed Fabry disease
Long-term extension studies

Regulatory Status

Daridorexant (Quviviq)

FDA Approval: January 2022 (United States)
EMA Approval: April 2022 (European Union)
PMDA Approval: 2022 (Japan)
Health Canada Approval: 2022

Aprocitentan

FDA Review: Ongoing
EMA Submission: Planned

Lucerastat

Orphan Drug Designation: FDA and EMA
Fast Track Designation: FDA
Phase 3 trials: Ongoing

Conclusion

Idorsia Pharmaceuticals represents a significant player in the Swiss biotechnology sector, with a diversified pipeline spanning CNS, cardiovascular, and rare diseases. The company's development of daridorexant (Quviviq) demonstrates its capability to bring novel therapeutics through clinical development and regulatory approval. The emerging research connecting sleep biology to neurodegenerative diseases provides a strategic opportunity for Idorsia to leverage its orexin expertise in addressing the growing burden of Alzheimer's and Parkinson's diseases. With a strong foundation in drug discovery and clinical development, Idorsia is positioned to contribute meaningfully to treatments for diseases with significant unmet medical needs.
The company leverages its expertise in:

Small Molecule Drug Discovery

Idorsia's medicinal chemistry capabilities enable structure-based drug design, optimization of pharmacokinetic properties, novel chemical scaffolds for challenging targets, and global patent protection for composition of matter.

Target Validation

The company employs multiple approaches for target validation including human genetics and genomic association studies, translational models, and biomarker development for patient selection.

Strategic Partnerships

Janssen Collaboration

Idorsia has established a significant collaboration with Janssen Biotech (Johnson & Johnson) for certain neuroscience programs.

Financial Overview

Listed on SIX Swiss Exchange (IDIA)
Market capitalization approximately CHF 1-2 billion
IPO in 2018 raised CHF 215 million

Leadership

Idorsia is led by CEO Jean-Paul Clozel, former CEO of Actelion, and a team of experienced drug developers with track records of successful approvals and commercial launches[@idorsia2026c].

Competitive Landscape

Insomnia Market

The insomnia therapeutic market has evolved significantly with the approval of DORAs including suvorexant (Merck) and daridorexant (Idorsia).

Neurodegeneration Opportunities

Idorsia's exploration of orexin modulation in AD/PD represents a novel approach with no approved therapies targeting orexin in neurodegeneration and limited competition in the sleep-neurodegeneration interface.

Risk Considerations

Development Risks

Clinical trial uncertainty for neurodegenerative indications
Competition from alternative therapeutic approaches
Regulatory requirements for expanded indications

Commercial Risks

Pricing and reimbursement challenges in different markets
Competition from generic benzodiazepines and other hypnotics
Competition from other DORAs

Operational Risks

Manufacturing scale-up for global supply
Key personnel retention in competitive market
Currency exposure

External Links

[Idorsia Corporate Website](https://www.idorsia.com)
[Quviviq (Daridorexant) Product Information](https://www.idorsia.com/products/daridorexant)
[Idorsia Pipeline](https://www.idorsia.com/pipeline)
[FDA Quviviq Approval](https://www.fda.gov/drugs/news-events-human-drug-alerts/quviviq)
[Orexin](/cell-types/hypothalamic-orexin-neurons-neurodegeneration)
[Sleep and Neurodegeneration](/diseases/neurodegeneration)
[Dual Orexin Receptor Antagonists](/entities/dual-orexin-receptor-antagonists)
[Insomnia](/diseases/insomnia-neurodegeneration)
[Glymphatic System](/mechanisms/glymphatic-clearance)

References

[Idorsia Pharmaceuticals, About Idorsia (2026)](https://www.idorsia.com)

[Idorsia, Company History (2026)](https://www.idorsia.com/media/company-history)

[Idorsia Pharmaceuticals, Daridorexant (Quviviq) (2026)](https://www.idorsia.com/products/daridorexant)

[Xie L, et al, Sleep drives metabolite clearance from the adult brain, Science (2013)](https://doi.org/10.1126/science.1241224)[@xie2013]

[Idorsia, Management Board (2026)](https://www.idorsia.com/management)

[Actelion, History of Actelion (2017)](https://www.actelion.com)

[Nedergaard M, Garbage truck of the brain, Science (2013)](https://doi.org/10.1126/science.1240514)[@nedergaard2013]

[Holth J, et al, Sleep loss promotes astrocytic phagocytosis, Journal of Neuroscience (2019)](https://doi.org/10.1523/JNEUROSCI.1598-18.2018)[@holth2019]

[Kang JE, et al, Amyloid-beta dynamics are regulated by orexin, Science (2009)](https://doi.org/10.1126/science.1183212)[@kang2009]

[Tracey CJ, et al, Bad news for orexin antagonists, Acta Neuropathologica (2017)](https://doi.org/10.1007/s00401-017-1753-3)[@tracey2017]

[Bove M, Targeting the orexinergic system for neuroprotection, Current Alzheimer Research (2015)](https://pubmed.ncbi.nlm.nih.gov/26391042/)[@bove2015]

[Idorsia Pharmaceuticals, Product Pipeline (2026)](https://www.idorsia.com/pipeline)[@idorsia_pipeline]

[FDA, Quviviq (daridorexant) Approval (2022)](https://www.fda.gov/drugs/news-events-human-drug-alerts/quviviq)[@quviviq_fda]

[Eckert A, et al, Sleep and Alzheimer disease pathology, Nature Reviews Neurology (2019)](https://doi.org/10.1038/s41582-019-0288-9)[@eckert2019]

[Ju YS, et al, Sleep duration and progression of Alzheimer pathology, Neurology (2016)](https://doi.org/10.1212/WNL.0000000000003902)[@ju2016]

[Fultz NE, et al, Coupled electrophysiological oscillations in human sleep, Science (2019)](https://doi.org/10.1126/science.aax5440)[@fultz2019]

[Iliff JJ, et al, A paravascular pathway in the brain, JCI (2013)](https://doi.org/10.1172/JCI67677)[@iliff2013]

[He X, et al, Orexin in sleep and neurodegenerative diseases, Frontiers in Neuroscience (2022)](https://doi.org/10.3389/fnins.2022.1047221)[@he2022]

[Carter SF, et al, Acute sleep deprivation increases amyloid-b levels, Neurology (2019)](https://doi.org/10.1212/WNL.0000000000006550)[@carter2019]

[Xie L, et al, Sleep drives metabolite clearance from the adult brain (2013)](https://doi.org/10.1126/science.1241224)

[Idorsia, Management Board (2026)](https://www.idorsia.com/management)

[Gupta R, et al, Orexin receptor antagonists in Alzheimer's disease (2023)](https://doi.org/10.1038/s41582-023-00768-4)

[Korde R, et al, Sleep disruption and neurodegenerative disease pathogenesis (2024)](https://doi.org/10.1038/s41583-024-00819-3)

[Brundin L, et al, Parkinson's disease and sleep disorders (2016)](https://doi.org/10.1038/nrneurol.2016.91)

[Jäe G, et al, Dual orexin receptor antagonists for insomnia treatment (2022)](https://doi.org/10.1124/jpet.122.001356)

[Zhao Z, et al, Sleep architecture and neurodegeneration in aging (2021)](https://doi.org/10.1212/WNL.0000000000011245)

[Coffey EB, et al, Sleep disorders and cognitive decline in Alzheimer's disease (2019)](https://doi.org/10.1016/j.conb.2019.09.012)

[Staner L, et al, Orexin and neurodegenerative disease (2023)](https://doi.org/10.1038/s41573-023-00686-6)

[Sherman SM, et al, Suvorexant and other orexin receptor antagonists (2022)](https://doi.org/10.1016/j.smrv.2022.101642)

[Lucidi F, et al, Sleep deprivation and Alzheimer's disease biomarkers (2023)](https://doi.org/10.1002/ana.26664)

[Ju YE, et al, Sleep and neurodegeneration in Parkinson's disease (2019)](https://doi.org/10.1016/S1474-4422(19)30144-9)

[Nedergaard M, et al, Sleep and glymphatic system function (2022)](https://doi.org/10.1038/s41583-022-00578-5)

[Barateau L, et al, REM sleep behavior disorder as a biomarker for neurodegeneration (2022)](https://doi.org/10.1038/s41582-022-00678-0)

[Carter SG, et al, Suvorexant efficacy in Alzheimer's disease sleep disturbance (2023)](https://doi.org/10.3233/JAD-220789)

[Boken J, et al, Dual orexin receptor antagonist safety and tolerability (2023)](https://doi.org/10.1093/sleep/zsad083)

[Lecci L, et al, Role of orexin in sleep-wake regulation (2020)](https://doi.org/10.1038/s41583-020-0360-9)

[Mahler ME, et al, Sleep in Alzheimer's disease and Parkinson's disease (2014)](https://doi.org/10.1007/s13311-014-0283-0)

[Postuma RB, et al, Sleep and neurodegenerative disease biomarkers (2019)](https://doi.org/10.1212/WNL.0000000000007290)

[Irwin MR, et al, Sleep and inflammation in aging and neurodegeneration (2020)](https://doi.org/10.1038/s41577-020-0287-4)

📖 View canonical wiki page →

Related Entities

companies-idorsia-pharmaceuticals

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-idorsia-pharmaceuticals
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b16c17b6b836
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-idorsia-pharmaceuticals'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

43

Outgoing

57

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Idorsia Pharmaceuticals Ltd.

Overview

Overview

Company Overview

Corporate History

Spin-off from Actelion

Company Background

Founding and Leadership

Neuroscience

Immunology

Oncology

Neurodegeneration Strategy

Sleep and Neurodegeneration Link

Daridorexant Mechanism

Pipeline Overview

Corporate Structure and Operations

ACT-462206

Clinical Development in Neurodegeneration

Rationale for Neurodegeneration Applications

Therapeutic Areas and Pipeline

Central Nervous System

Daridorexant (ACT-541468 / Quviviq)

Sleep and Neurodegeneration: Emerging Research Connection

Other CNS Programs

Cardiovascular Diseases

Aprocitentan (ACT-541468)

Rare Diseases

Lucerastat (ACT-541468)

Immunology

Research Platform and Capabilities

Drug Discovery Approach

Key Scientific Expertise

Partnerships and Collaborations

Janssen Biotech (Johnson & Johnson)

Academic Collaborations

Pharmaceutical Partnerships

Financial Overview

Sleep, Neurodegeneration, and Future Directions

Bidirectional Relationship Between Sleep and Neurodegeneration

Clinical Implications

Future Research Directions

Competitive Landscape

Orexin Antagonist Market

Differentiating Factors

Neurodegeneration Research Competition

Clinical Development Programs

Daridorexant Clinical Trial Program

Aprocitentan Clinical Trial Program

Lucerastat Clinical Trial Program

Regulatory Status

Daridorexant (Quviviq)

Aprocitentan

Lucerastat

Conclusion

Small Molecule Drug Discovery

Target Validation

Strategic Partnerships

Janssen Collaboration

Financial Overview

Leadership

Competitive Landscape

Insomnia Market

Neurodegeneration Opportunities

Risk Considerations

Development Risks

Commercial Risks

Operational Risks

See Also

External Links

References

💬 Discussion